The trial is due to last three years, although preliminary results are expected in 2011 and further results in 2012. Good results from the trial could give ITGI's competitive position a strong boost. The company's Over-and-Under heterologous tissue covered stent already has EU CE Mark Certification, and the company has applied for US Food and Drug Administration (FDA) approval.
ITGI's share price rose 0.5% today to NIS 0.64, giving a market cap of NIS 41 million.
You comment was recieved and soon will be published.
Thank you for posting your comment, which will be reviewed for publication.
Load more comments